CRISPR Therapeutics Expands Beyond Gene Editing to Fight Blood Clots
From orbit, Earth looks like a calm blue marble. But zoom in on the United States, and a silent crisis unfolds every year. Up to 900,000 people suffer from venous thromboembolism, a condition where blood clots form in veins. [3] Between 60,000 and 100,000 of them die annually. [3] That is a mortality rate comparable to a small city vanishing each year. The irony is stark. The most advanced gene-editing tool ever created, CRISPR, is currently used mainly for rare diseases affecting thousands. Yet the same technology could address a condition affecting nearly a million people annually. This gap between what is and what could be defines the current state of CRISPR Therapeutics.
CRISPR Therapeutics has one commercialized therapy, Casgevy, which treats sickle cell disease and transfusion-dependent beta thalassemia. The patient population for these rare disorders is limited compared to the 900,000 Americans facing blood clots annually. The company’s newest acquisition targets this larger market.
The company recently paid Sirius Therapeutics $95 million for the rights to CTX611, a long-acting small interfering RNA (siRNA) therapy. Unlike gene editing, which alters DNA directly, siRNA silences messenger RNA for coagulation factor XI in the liver. Reducing this factor lowers blood clot risk. Traditional blood thinners like warfarin carry a serious side effect: excessive bleeding. CTX611 targets a specific coagulation pathway to avoid that problem. The U.S. anticoagulant market is estimated at $20 billion annually.
A Parallel Bet on Off-the-Shelf CAR-T
CRISPR
Therapeutics is also developing off-the-shelf allogeneic CAR-T therapies, where cells come from healthy donors rather than the patient. This approach eliminates the weeks-long personalized manufacturing process, enabling immediate treatment and standardized dosing.
The company is developing off-the-shelf allogeneic CAR-T therapies. The word allogeneic means the cells come from a donor, not from the patient. This simple shift changes everything. Instead of waiting weeks for a personalized manufacturing process, patients can be treated immediately. The cells are sourced from healthy, vetted donors. A single manufacturing batch can yield dozens of standardized doses. This reduces per-dose production costs dramatically. It simplifies logistics and improves scalability. Perhaps most importantly, physicians can redose patients as needed to achieve or maintain remission. With autologous therapies, redosing is often impossible because the patient’s cells are exhausted or the disease has progressed too far.
The next-generation candidates are called CTX112 and CTX131. CTX112 targets CD19-positive B-cell cancers. These are cancers that arise from B cells, a type of white blood cell. But CTX112 has another application. It is being evaluated for severe autoimmune conditions, including systemic lupus erythematosus and lupus nephritis. The goal is to reset the immune system by depleting B cells. This is a radical departure from the traditional approach to autoimmune diseases. Instead of managing symptoms with immunosuppressive drugs, the therapy aims to reboot the immune system entirely. The implications for patients with severe autoimmune flare-ups are profound. They no longer have to wait months for a personalized treatment. They can receive immediate care.
Financial Progress Remains Modest
The financial picture for CRISPR Therapeutics is improving, though progress is gradual. In the second quarter, the company reported revenue of $10.2 million. That is a significant jump from $892,000 in the same period a year earlier. The loss per share also narrowed. It was $0.94, compared to a loss of $2.40 per share in the same period a year earlier. These numbers show a company moving in the right direction, but they also reveal the scale of the challenge. The company has never shown a profit. Its stock is up only slightly more than 8% this year. The Nasdaq Biotechnology index, by comparison, has returned 27%. The S&P 500 has returned 12%. CRISPR Therapeutics is underperforming both benchmarks.
The cash position is stronger now. Following a stock sale, the company holds $2.36 billion in cash. That is up 19.2% from the same period a year ago. This financial cushion should allow the company to fund its broad pipeline through multiple phase 1 and phase 2 clinical readouts. The key phrase here is without needing additional dilutive equity financing. In other words, the company should not need to issue more shares in the near term. This is important for existing shareholders because issuing new shares dilutes their ownership stake. The disciplined operational and financial management is evident. But the main source of revenue remains Casgevy, and that revenue is shared with a partner.
Vertex Pharmaceuticals handles the primary commercialization of Casgevy. CRISPR Therapeutics receives 40% of the net profits. The uptake among patients has been slow. The treatment process, from cell collection to reinfusion, takes several months. This is not a quick fix. However, the ramp-up in patient initiations and insurance coverage approvals provides visible revenue momentum over multiple quarters. On July 1, the U.S. Food and Drug Administration approved Casgevy for children 2 years of age and older with sickle cell disease or transfusion-dependent beta thalassemia. [2] This is the first genetic therapy indicated for children as young as 2 for both conditions. With this approval, CRISPR Therapeutics says that 5,500 patients with these disorders may be eligible for treatment for the first time. The expansion into pediatric populations would further expand the total addressable market for the therapy.
The company’s financial trajectory remains uncertain. Revenue is growing from a small base, and losses are narrowing but persistent. Cathie Wood’s Ark Invest ETFs hold 94.6 million shares at an average price of $66; the current price is around $52. Whether the pipeline delivers on its promise will depend on upcoming clinical readouts.